Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology

被引:39
作者
Goasguen, JE
Zandecki, M
Mathiot, C
Scheiff, JM
Bizet, M
Ly-Sunnaram, B
Grosbois, B
Monconduit, M
Michaux, JL
Facon, T
机构
[1] Univ Rennes, Hop SUD, F-35056 Rennes, France
[2] Univ Angers, Angers, France
[3] Free Univ Brussels, Brussels, Belgium
[4] Univ Lille, Lille, France
[5] Univ Paris, Inst Curie, IFM, F-75252 Paris, France
[6] Univ Rouen, Rouen, France
关键词
multiple myeloma; plasma cells; morphology;
D O I
10.1016/S0145-2126(99)00132-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The relationship between plasmablastic cells and outcome in multiple myeloma (MM) has been established for nearly 15 years. Bur the assessment of these cells is not easy to perform and it allows the identification of only a small proportion of patients. We investigated the plasma cell morphology using a progressive evaluation of consecutive criteria: nucleolus, chromatin and nuclear-cellular ratio (N/C). The combination of these three items produces a subclassification where four cellular subtypes identify 93% of the plasma cells, and these subtypes are related to the outcome. The interest of this methodology is to be based on the mature plasma cells that are easier to identify than the plasmablastic cells. These new cell subtypes introduce a new classification for patients: Group 1 includes patients with at leas than 66% mature plasma cells (P000). Both Group 2 and 3 have less than 66% P000 and are separated by their degree of maturation (Proplasma I greater than or equal to Proplasma II + plasmablastic). The distinction of these three groups of patients is highly related to the prognosis (P < 10(-4)). These results have been confirmed on a second group of patients coming from a different institution. In conclusion, we propose a new methodology for the plasma cell evaluation in MM, that is based on the morphological criteria and that has the advantage of identifying an intermediate (30%) subgroup of patients with a prognostic significance. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1133 / 1140
页数:8
相关论文
共 14 条
[1]   BONE-MARROW HISTOLOGY IN MYELOMA - ITS IMPORTANCE IN DIAGNOSIS, PROGNOSIS, CLASSIFICATION AND STAGING [J].
BARTL, R ;
FRISCH, B ;
BURKHARDT, R ;
FATEHMOGHADAM, A ;
MAHL, G ;
GIERSTER, P ;
SUND, M ;
KETTNER, G .
BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (03) :361-375
[2]  
CARTER A, 1987, CANCER, V60, P1060, DOI 10.1002/1097-0142(19870901)60:5<1060::AID-CNCR2820600522>3.0.CO
[3]  
2-3
[4]  
FRITZ E, 1984, BLOOD, V63, P1072
[5]  
GENTILHOME O, 1996, NOUV REV FR HEMATOL, V37, pA278
[6]  
Goasguen JE, 1997, BLOOD, V90, P4091
[7]  
GOASGUEN JE, 1994, BLOOD, V84, pA654
[8]   Plasmablastic morphology - An independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group [J].
Greipp, PR ;
Leong, T ;
Bennett, JM ;
Gaillard, JP ;
Klein, B ;
Stewart, JA ;
Oken, MM ;
Kay, NE ;
Van Ness, B ;
Kyle, RA .
BLOOD, 1998, 91 (07) :2501-2507
[9]  
GREIPP PR, 1985, BLOOD, V65, P305
[10]  
GROSBOIS B, 1993, BLOOD, V82, pA263